Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Triple-negative (TNBC) is the most lethal subtype of breast cancer owing to high
heterogeneity, aggressive nature, and lack of treatment options. Chemotherapy remains the …

Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype
to treat. To date, therapies directed to specific molecular targets have rarely achieved …

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple
entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite …

As the most commonly occurring cancer in women worldwide, breast cancer poses a
formidable public health challenge on a global scale. Breast cancer consists of a group of …

Abstract Purpose of Review Apoptosis is a major mechanism of cancer cell death. Thus,
evasion of apoptosis results in therapy resistance. Here, we review apoptosis modulators in …

The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops
resistance to chemotherapy. An unresolved question is whether resistance is caused by the …

Breast cancer is a heterogeneous disease and differs greatly among different patients
(intertumor heterogeneity) and even within each individual tumor (intratumor heterogeneity) …

Most patients with advanced triple-negative breast cancer (TNBC) develop drug resistance.
MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant …